

ERRATUM

Open Access



Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Colin Reisner^{1*}, Leonardo M. Fabbri², Edward M. Kerwin³, Charles Fogarty⁴, Selwyn Spangenthal⁵, Klaus F. Rabe^{6,7}, Gary T. Ferguson⁸, Fernando J. Martinez⁹, James F. Donohue¹⁰, Patrick Darken¹, Earl St. Rose¹, Chad Orevillo¹, Shannon Strom¹¹, Tracy Fischer¹¹, Michael Golden¹¹ and Sarvajna Dwivedi¹²

Erratum

Upon Publication of the original article [1] several discrepancies were highlighted in the following sections; Results, Table 1, Table 2 and Fig. 3. These errors have since been acknowledged and corrected in this erratum

The first sentence in the subsection “Baseline characteristics” originally read: Patients’ baseline and demographic characteristics are shown in Table 1 (mITT population).

This should read: Patients’ baseline and demographic characteristics are shown in Table 1.

The header of Table 1 read: Baseline demographics (mITT population)

This should read as: Baseline demographics (ITT population)

It was noticed that Table 2 contained an error. In Table 2, data row 2, the footnote symbol ‘c’ was erroneously included in the third column. The footnote symbol ‘c’ should be placed in the second column in this row. The corrected Table 2 is shown below.

It was noticed that in Fig. 3b, the error bar on the 4th data point (AUC_{inf}) was incorrectly given. The error bar

on the 4th data point (AUC_{inf}) should range from 74.88, to 103.28 The corrected Fig. 3b is shown below.

These corrections do not change the conclusions of the article.

Author details

¹Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA. ²Department of Medicine, University of Modena and Reggio Emilia, NOCSAE, Modena, Italy. ³Clinical Research Institute of Southern Oregon, Medford, OR, USA. ⁴Spartanburg Medical Research, Spartanburg, NC, USA. ⁵American Health Research, Charlotte, NC, USA. ⁶Lungen Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany. ⁷Department of Medicine, Christian-Albrechts University Kiel, Kiel, MI, USA. ⁸Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA. ⁹Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College; New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA. ¹⁰Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. ¹¹Pearl Therapeutics Inc., Durham, NC, USA. ¹²Pearl Therapeutics Inc., Redwood City, CA, USA.

Received: 7 August 2017 Accepted: 7 August 2017

Published online: 21 August 2017

Reference

1. Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, Rose ES. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel co-suspension™ delivery technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. *Respir Res.* 2017 Jan 6;18(1):8.

* Correspondence: creisner@pearltherapeutics.com

¹Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA

Full list of author information is available at the end of the article



Table 2 FEV₁, AUC₀₋₁₂ at Day 7: GFF MDI 72/9/6 µg and 36/9/6 µg comparisons (mITT population)

Comparator	LSM treatment differences for GFF MDI in FEV ₁ , AUC ₀₋₁₂ at Day 7							
	GFF MDI 72/9/6 µg	36/9/6 µg	GP MDI 36 µg	Open-label tiotropium 18 µg	FF MDI 9.6 µg	7.2 µg	Placebo MDI	Open-label FF ^a DPI 12 µg
GFF MDI 72/9/6 µg								
LSM ^b difference (SE), L	NA	0.008 (0.0236)	0.109 (0.0250) [†]	0.103 (0.0216) [†]	0.116 (0.0245) [†]	0.124 (0.0237) [†]	0.298 (0.0261) [†]	0.101 (0.0241) [†]
95% CI		-0.039, 0.054 ^c	0.059, 0.158	0.060, 0.145	0.068, 0.165	0.078, 0.171	0.247, 0.349	0.053, 0.148
GFF MDI 36/9/6 µg								
LSM ^b difference (SE), L	See above	NA	0.101 (0.0245) [†]	0.095 (0.0213) [†]	0.109 (0.0242) [†]	0.116 (0.0236) [†]	0.290 (0.0261) [†]	0.093 (0.0241) ^{***}
95% CI			0.053, 0.149	0.053, 0.137	0.061, 0.156	0.070, 0.163	0.239, 0.342	0.045, 0.140

*** p < 0.001; [†]p < 0.0001

^aForadil® Aerolizer[®]; ^bLSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid bias in treatment effect estimates; ^cnon-inferiority comparison CI, confidence interval; DPI, dry powder inhaler; FEV₁, AUC₀₋₁₂, forced expiratory volume in 1 s area under the curve from 0 to 12 h post-dose; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler; mITT, modified intent-to-treat; NA, not available; SE, standard error




Fig. 3 Ratio of geometric LSMs and 90% CIs. **(a)** GFF MDI 36/9.6 µg versus GP MDI 36 µg **(b)** GFF MDI 36/9.6 µg versus FF MDI 9.6 µg **(c)** FF MDI 9.6 µg versus FF DPI (PK-mITT population). ^aLSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid bias in treatment effect estimates. ^bForadil® Aerolizer® AUC_{0-inf}, area under the curve from time 0 to infinity; AUC₀₋₁₂, area under the curve from 0 to 12 h post-dose; CI, confidence interval; C_{max}, maximum observed plasma concentration; DPI, dry powder inhaler; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler; PK-mITT, pharmacokinetic modified intent-to-treat